Durect Corporation Stock News

Shares of Durect (NASDAQ: DRRX) were up 23% at 1:53 p.m. EDT on Tuesday. The gains followed the release of first-quarter results after the closing bell Monday and disappointing trial results for Ge

Durect (DRRX) delivered earnings and revenue surprises of -25.00% and -41.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2020 and provided a corporate update.

The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...

CUPERTINO, Calif., May 4, 2020 DURECT Corporation (Nasdaq: DRRX) today announced that it will report first quarter 2020 financial results and host a conference call after the market close on Monday, M

Durect (DRRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DURECT expects an FDA decision for its postoperative pain drug POSIMIR in the coming months, FDA approval will allow biotech to search for commercial partner. A

Shares of DURECT Co. (NASDAQ:DRRX) have been assigned an average recommendation of “Buy” from the seven ratings firms that are presently covering the firm, MarketBeat reports. Two analysts have ra

Q4 2019 DURECT Corp Earnings Call

In a report issued on March 13, Mayank Mamtani from B.Riley FBR maintained a Buy rating on Durect (DRRX), with a price target of $5.00. The company's

In a report issued on March 13, Mayank Mamtani from B.Riley FBR maintained a Buy rating on Durect ( DRRX – Research Report ), with a price target of $5.00 . The company’s shares closed last Monday